NCCN Receives $4 Million in Oncology Research Funding from GlaxoSmithKline

NCCN recently received two individual $2 million research grants from GlaxoSmithKline to evaluate the effectiveness of ofatumumab in hematologic malignancies and pazopanib in the treatment of solid tumors. Investigators from NCCN Member Institutions are eligible to apply for the research funding. July 27, 2010 FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCCN) has been awarded two individual $2 million grants from GlaxoSmithKline (GSK) to support clinical stud...
Source: National Comprehensive Cancer Network Oncology Research Program - Category: Cancer & Oncology Source Type: news